Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Established in April 2023, Stony Brook University’s Center for Healthy Aging aims to promote healthy aging and extend physical and mental well-being through innovative research solutions. Please join them for our inaugural virtual seminar series.
As we age, changes in our “epigenome” alter how our genes are regulated, ultimately impacting organ function. Our research focuses on understanding epigenomic changes in different organs. In this presentation, I will focus on skeletal muscle, which makes up 40% of our body weight and plays a key role in metabolism. As we age, our muscles tend to weaken, partly because the stem cells in our muscles that help repair and grow reduce in number and function. In our study, we looked at muscle stem cells from young, old, and geriatric mice and uncovered that as these cells age, they show signs of increased immune activity and start to lose their ability to stay dormant, which is vital for their function. We also identified specific areas of the genome that might be responsible for these changes. By targeting these areas, we could potentially restore the function of these stem cells and help maintain muscle health as we age.
Upcoming Topics & Dates:
October 30th, 11 am: Samantha Rossano, PhD, Medical Science Liaison, Life Molecular Imaging, Inc., Brain imaging biomarkers in Alzheimer’s disease
November 20th, 11 am: Gregorio Valdez, PhD, GLF Translational Associate Professor of Molecular Biology, Cell Biology and Biochemistry, Brown University, Slowing muscle degeneration
February 26th, 11 am: Christopher Barrett Bowling, MD, MSPH, Associate Professor of Medicine, Associate Professor in Population Health Sciences, Senior Fellow of the Center for the Study of Aging and Human Development, Duke University, Geriatricizing chronic disease research
March 26th, 11 am: Dr. Frank Lin, MD, PhD, Director of the Cochlear Center for Hearing and Public Health, Professor of Otolaryngology, Medicine, Mental Health, and Epidemiology, Johns Hopkins University Team, Baltimore HEARS and the Baltimore Longitudinal Study of Aging
April 30th, 11 am: Dennis Selkoe, MD, Vincent and Stella Coates Professor of Neurologic Diseases, Harvard University, Role of soluble oligomers of amyloid beta in synaptic injury
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4252
[post_author] => 4
[post_date] => 2023-07-10 12:52:21
[post_date_gmt] => 2023-07-10 16:52:21
[post_content] =>
The Life Sciences Summit 2023 is returning to New York City - In Person - on October 11th at the Alexandria Center for Life Science. Save the date to join us in the fall and visit lifesciencessummit.org for program and registration updates.
DepYmed, Inc., has announced a new financing led by Topspin Fund, L.P. and additional investors for a total of $8.3 million.
Led by former Center for Biotech BioEntrepreneur-in-Residence Andreas Grill, DepYmed is a pharmaceutical company focused on a novel phosphatase inhibition technology platform with potential therapeutic application across multiple different disease including Rett Syndrome, Wilson Disease and Breast Cancer.
[post_title] => DepYmed Secures $8.3M Financing
[post_excerpt] => Led by former Center for Biotech BioEntrepreneur-in-Residence Andreas Grill, DepYmed has announced a new financing led by Topspin Fund, L.P.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => depymed-secures-8-3m-financing
[to_ping] =>
[pinged] =>
https://depymedinc.com/2021/04/depymed-inc-announces-8-3-million-financing/
[post_modified] => 2021-09-20 16:07:40
[post_modified_gmt] => 2021-09-20 16:07:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3762
[menu_order] => 47
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 3157
[post_author] => 3
[post_date] => 2019-02-25 20:01:55
[post_date_gmt] => 2019-02-25 20:01:55
[post_content] => Women life science entrepreneurs: Springboard Enterprises is now accepting application for the 2019 Health Innovation Hub: Life Sciences track.
Springboard’s Health Innovation Hub: Life Sciences 2019 is a year-long program for women-led seeking growth funding and expert connections to develop solutions in healthcare, including new drugs, diagnostics, pharma technologies, treatments for rare diseases, and medical devices. Those selected for the program will be matched with a personal advisory team of experts and invited to participate in several in-person and virtual sessions, workshops, and presentation opportunities.
Priority Deadline is March 1! Full information on the program can be found at sb.co/HIH
[post_title] => Application Open: Springboard Enterprises 2019 Health Innovation Hub: Life Sciences
[post_excerpt] => Women life science entrepreneurs: Springboard Enterprises is now accepting application for the 2019 Health Innovation Hub: Life Sciences track.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => application-open-springboard-enterprises-2019-health-innovation-hub-life-sciences
[to_ping] =>
[pinged] =>
[post_modified] => 2019-04-09 14:40:56
[post_modified_gmt] => 2019-04-09 14:40:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3157
[menu_order] => 101
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
